<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04840667</url>
  </required_header>
  <id_info>
    <org_study_id>SHP675-301</org_study_id>
    <secondary_id>2018-004689-32</secondary_id>
    <nct_id>NCT04840667</nct_id>
  </id_info>
  <brief_title>A Study of Replagal in Treatment-naïve Adults With Fabry Disease</brief_title>
  <official_title>A Phase 3, Open-label Study to Evaluate the Efficacy and Safety of REPLAGAL® in Treatment-naïve Subjects With Fabry Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, adults with Fabry Disease who have not had any treatment for this condition&#xD;
      will be treated with Replagal. The main aim of the study is to check if Replagal improves&#xD;
      kidney function and heart structure of participants with Fabry Disease. Participants will&#xD;
      receive one Replagal infusion every other week for up to 104 weeks. They will visit the&#xD;
      clinic every 12 to 14 weeks during treatment with a follow-up visit 2 weeks after treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 8, 2021</start_date>
  <completion_date type="Anticipated">May 31, 2027</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2027</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Renal Function at Week 104</measure>
    <time_frame>Baseline, Week 104</time_frame>
    <description>Renal function is assessed by estimated glomerular filtration rate (eGFR) using Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula. The eGFR will be calculated by CKD-EPI formula:&#xD;
eGFR = 141 x min (Serum Creatinine [Scr]/κ,1)^(α) x max(Scr/κ,1)^(-1.209) x 0.993^(Age) x 1.018 (if female) x 1.159 (if black) where: Scr is serum creatinine (mg/dL); κ is 0.7 for females and 0.9 for males; α is -0.329 for females and -0.411 for males; min indicates the minimum of Scr/κ or 1; max indicates the maximum of Scr /κ or 1. Change from baseline in renal function at Week 104 will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Cardiac Structure at Week 104</measure>
    <time_frame>Baseline, Week 104</time_frame>
    <description>Cardiac structure is assessed by left ventricular mass index (LVMI) using cardiac magnetic resonance imaging (cMRI). Change from baseline in cardiac structure at Week 104 will be assessed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Annualized Rate of Change in Estimated Glomerular Filtration Rate (eGFR) up to Week 104</measure>
    <time_frame>Baseline, up to Week 104</time_frame>
    <description>Annualized rate of change in eGFR up to Week 104 will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annualized Rate of Change in Left Ventricular Mass Index (LVMI) up to Week 104</measure>
    <time_frame>Baseline, up to Week 104</time_frame>
    <description>Annualized rate of change in LVMI up to Week 104 will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) up to Week 104</measure>
    <time_frame>Baseline, up to Week 104</time_frame>
    <description>Change from baseline in eGFR up to Week 104 will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Left Ventricular Mass Index (LVMI) up to Week 104</measure>
    <time_frame>Baseline, up to Week 104</time_frame>
    <description>Change from baseline in LVMI up to Week 104 will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Proteinuria up to Week 104</measure>
    <time_frame>Baseline, up to Week 104</time_frame>
    <description>Proteinuria will be measured based on protein/creatinine ratio (PCR). Change from baseline in proteinuria up to Week 104 will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Cardiac Fibrotic Segments up to Week 104</measure>
    <time_frame>Baseline, up to Week 104</time_frame>
    <description>Change from baseline in cardiac fibrotic segments suggestive of cardiac fibrosis up to Week 104 will be assessed by volume of fibrosis, measured by cMRI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Interventricular Septal End-Diastolic Thickness and Posterior Wall Thickness in Diastole up to Week 104</measure>
    <time_frame>Baseline, up to Week 104</time_frame>
    <description>Change from baseline in interventricular septal end-diastolic thickness and posterior wall thickness in diastole up to Week 104 will be measured by cMRI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Plasma Globotriaosylsphingosine (lyso-Gb3) up to Week 104</measure>
    <time_frame>Baseline, up to Week 104</time_frame>
    <description>Change from baseline in lyso-Gb3 up to Week 104 will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events (AEs)</measure>
    <time_frame>From start of study drug administration up to follow-up (Week 106)</time_frame>
    <description>An adverse event (AE) is any untoward medical occurrence in a clinical investigation participants administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Will Develop Anti-drug Antibodies (ADA) to REPLAGAL</measure>
    <time_frame>Baseline, up to Week 104</time_frame>
    <description>Number of participants who will develop ADA to REPLAGAL will be assessed.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Fabry Disease</condition>
  <arm_group>
    <arm_group_label>REPLAGAL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive REPLAGAL 0.2 milligram per kilogram (mg/kg) body weight of intravenous (IV) infusion Every Other Week (EOW) for 104 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>REPLAGAL</intervention_name>
    <description>Participants will receive REPLAGAL 0.2 mg/kg body weight of IV infusion for 104 weeks.</description>
    <arm_group_label>REPLAGAL</arm_group_label>
    <other_name>SHP675</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The participant must voluntarily sign an Institutional Review Board (IRB)/Independent&#xD;
             Ethics Committee/Research Ethics Board approved informed consent form after all&#xD;
             relevant aspects of the study have been explained and discussed with the participant.&#xD;
&#xD;
          -  The participant has Fabry disease as confirmed at screening by the following criteria&#xD;
             using a dried blood spot (DBS) assay:&#xD;
&#xD;
               1. For male participants, Fabry disease is confirmed by a deficiency of&#xD;
                  alpha-galactosidase A (GLA) activity and a mutation in the GLA gene&#xD;
&#xD;
               2. For female participants, Fabry disease is confirmed by a mutation in the GLA gene&#xD;
&#xD;
          -  The participant is 18 to 65 years of age, inclusive.&#xD;
&#xD;
          -  Female participants must have a negative pregnancy test at screening.&#xD;
&#xD;
          -  Female participants of child-bearing potential must agree to use a medically&#xD;
             acceptable method of contraception at all times during the study and for at least 14&#xD;
             days after the final study infusion; the methods of acceptable contraception are&#xD;
             listed in the protocol.&#xD;
&#xD;
          -  The participant is deemed, as determined by the investigator, to have adequate general&#xD;
             health to undergo the specified protocol-related procedures and to have no safety or&#xD;
             medical contraindications for participation.&#xD;
&#xD;
          -  The participant has not received any treatment (approved or investigational) specific&#xD;
             to Fabry disease, such as enzyme replacement therapy (ERT), chaperone therapy, or&#xD;
             substrate reduction therapy.&#xD;
&#xD;
          -  The participant must have an eGFR of 45 to 120 milliliter per minute per 1.73 square&#xD;
             meter (mL/min/1.73 m^2); eGFR will be calculated by a Shire-designated laboratory&#xD;
             using the CKD-EPI formula. If the eGFR measurement at screening is not within the&#xD;
             range, a second eGFR measurement may be completed and, if in range, used as the&#xD;
             screening value. If a second measurement is taken, a minimum of 1 week and maximum of&#xD;
             30 days should separate it from the first. This inclusion criterion follows the&#xD;
             European Guidelines for Treatment of Fabry Disease and Kidney Disease Improving Global&#xD;
             Outcomes guidelines for classification of renal disease.&#xD;
&#xD;
          -  The participant has left ventricular hypertrophy (LVH), where LVH is defined as left&#xD;
             ventricular mass index (LVMI) greater than (&gt;) 50 gram per square meter (g/m^2.7)&#xD;
             confirmed by cardiac magnetic resonance imaging (cMRI) at screening. The cMRI value at&#xD;
             screening will serve as the baseline value.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  In the opinion of the investigator, the participant's life expectancy is less than or&#xD;
             equal to (&lt;=) 5 years.&#xD;
&#xD;
          -  The participant has undergone or is scheduled to undergo kidney transplantation or is&#xD;
             currently on dialysis, or has any signs or symptoms of end stage renal disease.&#xD;
&#xD;
          -  Protein/creatinine ratio (PCR) greater than (&gt;) 0.15 milligram per milligram (mg/mg)&#xD;
             female and &gt; 0.14 mg/mg male.&#xD;
&#xD;
          -  Participants who have clinically relevant history of allergy or signs or symptoms of&#xD;
             severe hypersensitivity, (including hypersensitivity to the REPLAGAL active substance&#xD;
             or any of the excipients), which in the investigator's judgment, will substantially&#xD;
             increase the participant's risk if he or she participates in the study.&#xD;
&#xD;
          -  Cardiac fibrosis involving more than 2 segments, as determined by cMRI at screening.&#xD;
&#xD;
          -  In the opinion of the investigator, the participant has non-Fabry disease-related&#xD;
             cause of end-organ (renal, cardiac, central nervous system) dysfunction/failure or is&#xD;
             receiving medications that may affect the rate of disease progression, as assessed by&#xD;
             cardiac and/or renal measures.&#xD;
&#xD;
          -  The participant has a positive test at screening for hepatitis B surface antigen,&#xD;
             positive test for hepatitis B core antibody, positive test for hepatitis C (HCV)&#xD;
             antibody with confirmation by HCV-ribonucleic acid polymerase chain reaction testing,&#xD;
             or positive test for human immunodeficiency virus antibody.&#xD;
&#xD;
          -  Treatment with REPLAGAL at any time prior to the study.&#xD;
&#xD;
          -  Prior treatment with any of the following medications:&#xD;
&#xD;
               1. FABRAZYME (agalsidase beta) and its biosimilars&#xD;
&#xD;
               2. GLYSET (miglitol)&#xD;
&#xD;
               3. ZAVESCA (miglustat)&#xD;
&#xD;
               4. CERDELGA (eliglustat)&#xD;
&#xD;
               5. GALAFOLD (migalastat)&#xD;
&#xD;
               6. Any investigational product for treatment of Fabry disease&#xD;
&#xD;
          -  Treatment at any time during the study with the following medications:&#xD;
&#xD;
               1. Chloroquine&#xD;
&#xD;
               2. Amiodarone&#xD;
&#xD;
               3. Monobenzone&#xD;
&#xD;
               4. Gentamicin&#xD;
&#xD;
          -  The participant is pregnant or lactating.&#xD;
&#xD;
          -  The participant has a body mass index &gt; 39 kilogram per square meter (kg/ m^2). (Body&#xD;
             mass index [BMI] = kg/ m^2).&#xD;
&#xD;
          -  The participant is treated or has been treated with any investigational drug within 30&#xD;
             days of study start.&#xD;
&#xD;
          -  The participant is unable to understand the nature, scope, and possible consequences&#xD;
             of the study.&#xD;
&#xD;
          -  The participant is unable to comply with the protocol, eg, uncooperative with protocol&#xD;
             schedule, refusal to agree to all of the study procedures, inability to return for&#xD;
             evaluations, or is otherwise unlikely to complete the study, as determined by the&#xD;
             investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Shire</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shire Contact</last_name>
    <phone>+1 866 842 5335</phone>
    <email>ClinicalTransparency@takeda.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Británico de Buenos Aires</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1280AEB</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>(+) 54 (0) 11-4309-6400</phone>
      <email>rcreisin@intramed.net</email>
    </contact>
    <investigator>
      <last_name>Ricardo Reisin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Melbourne Hospital</name>
      <address>
        <city>Parkville</city>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+61 3 9342 7119</phone>
      <email>kathy.nicholls@mh.org.au</email>
    </contact>
    <investigator>
      <last_name>Kathy Nicholls</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Brugmann</name>
      <address>
        <city>Brussel</city>
        <zip>1020</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>(+) 3224773315</phone>
      <email>prochore.kamgang@chu-brugmann.be</email>
    </contact>
    <investigator>
      <last_name>Prochore Kamgang Semeu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical center Banja Luka</name>
      <address>
        <city>Banja Luka</city>
        <zip>78000</zip>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>(+) 38765663997</phone>
      <email>tamara.kovacevic@medicolaser.info</email>
    </contact>
    <investigator>
      <last_name>Tamara Kovacevic</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>General Hospital Prim. dr. Abdulah Nakas</name>
      <address>
        <city>Sarajevo</city>
        <zip>71000</zip>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>(+) 387 61190490</phone>
      <email>merita.tiric@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Merita Tiric</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chronos Pesquisa Clínica</name>
      <address>
        <city>Brasilia</city>
        <zip>QNM 34</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>(+) 5561999024698</phone>
      <email>aspcarvalho@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Gerson da Silva Carvalho</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Clinicas de Porto Alegre (HCPA) - PPDS</name>
      <address>
        <city>Porto Alegre</city>
        <zip>90035-903</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>(+) 55 51 33596340</phone>
      <email>rgiugliani@hcpa.edu.br</email>
    </contact>
    <investigator>
      <last_name>Roberto Giugliani</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CEMEC - Centro Multidisciplinar de Estudos Clínicos</name>
      <address>
        <city>São Bernardo do Campo</city>
        <zip>09715-090</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>(+) 551149304243</phone>
      <email>dradre79@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Andressa Nijenhuis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vancouver General Hospital (VGH)</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>(+) (604) 875-4149</phone>
      <email>anna.lehman@vch.ca</email>
    </contact>
    <investigator>
      <last_name>Anna Lehman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth II Health Sciences Center</name>
      <address>
        <city>Halifax</city>
        <zip>B3H 1V7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>(902) 473-4023</phone>
      <email>mlwest@dal.ca</email>
    </contact>
    <investigator>
      <last_name>Michael West</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinicki bolnicki centar Zagreb</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>(+)38598359187</phone>
      <email>zreiner@kbc-zagreb.hr</email>
    </contact>
    <investigator>
      <last_name>Zeljko Reiner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Turun Yliopistollinen Keskussairaala</name>
      <address>
        <city>Turku</city>
        <zip>FI-20521</zip>
        <country>Finland</country>
      </address>
    </facility>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+35823130130</phone>
      <email>ilkka.kantola@tyks.fi</email>
    </contact>
    <investigator>
      <last_name>Ilkka Kantola</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vaasan Keskussairaala</name>
      <address>
        <city>Vaasa</city>
        <zip>65130</zip>
        <country>Finland</country>
      </address>
    </facility>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+35862131111</phone>
      <email>jukka.saarinen@vshp.fi</email>
    </contact>
    <investigator>
      <last_name>Jukka Saarinen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charité - Universitätsklinikum</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>(+) 49(0)30 450 614 288</phone>
      <email>sima.canaan@charite.de</email>
    </contact>
    <investigator>
      <last_name>Sima Canaan-Kuhl</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SphinCS</name>
      <address>
        <city>Hochheim</city>
        <zip>65239</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>(+) 496146904820</phone>
      <email>eugen.mengel@spincs.de</email>
    </contact>
    <investigator>
      <last_name>Eugen Mengel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin der Johannes Gutenberg-Universität Mainz</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>(+) 496131175754</phone>
      <email>julia.hennermann@unimedizin-mainz.de</email>
    </contact>
    <investigator>
      <last_name>Julia Hennermann</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fachinternistische Gemeinschaftspraxis</name>
      <address>
        <city>Müllheim</city>
        <zip>79379</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>(+) 49 7631 4084</phone>
      <email>dr.cybulla@f-g-m.de</email>
    </contact>
    <investigator>
      <last_name>Markus Cybulla</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Wuerzburg</name>
      <address>
        <city>Wuerzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>004993120139004</phone>
      <email>nordbeck_p@ukw.de</email>
    </contact>
    <investigator>
      <last_name>Peter Nordbeck</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Attikon University General Hospital</name>
      <address>
        <city>Athens</city>
        <zip>12462</zip>
        <country>Greece</country>
      </address>
    </facility>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>(+) 302105831000</phone>
      <email>gtsivou@med.uoa.gr</email>
    </contact>
    <investigator>
      <last_name>Georgios Tsivgoulis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University General Hospital of Heraklion</name>
      <address>
        <city>Heraklion</city>
        <zip>71110</zip>
        <country>Greece</country>
      </address>
    </facility>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>(+) 306977664913</phone>
      <email>eugenedaphnis@yahoo.gr</email>
    </contact>
    <investigator>
      <last_name>Evgenios Dafnis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of Ioannina</name>
      <address>
        <city>Ioannina</city>
        <zip>45500</zip>
        <country>Greece</country>
      </address>
    </facility>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>(+) 302651099653</phone>
      <email>evangeldou@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Evangelia Dounousi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Onasseio Private Practise Hospital of Piraeus</name>
      <address>
        <city>Kallithea</city>
        <zip>17674</zip>
        <country>Greece</country>
      </address>
    </facility>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>(+) 306944371061</phone>
      <email>anastasakis@ocsc.gr</email>
    </contact>
    <investigator>
      <last_name>Aris Anastasakis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Papageorgiou General Hospital of Thessaloniki</name>
      <address>
        <city>Thessaloniki</city>
        <zip>54645</zip>
        <country>Greece</country>
      </address>
    </facility>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>(+) 302313323272</phone>
      <email>nefros.papageorgiouhospital@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Dorothea Papadopoulou</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont</name>
      <address>
        <city>Szeged</city>
        <zip>6725</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>(+) 36302675845</phone>
      <email>sepp.robert@med.u-szeged.hu</email>
    </contact>
    <investigator>
      <last_name>Robert Sepp</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ASST Grande Ospedale Metropolitano Niguarda - Presidio Ospedaliero Ospedale Niguarda Ca' Granda</name>
      <address>
        <city>Milano</city>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>(+) 39 3209720487</phone>
      <email>enrico.minetti@ospedaleniguarda.it</email>
    </contact>
    <investigator>
      <last_name>Enrico Minetti</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U.O. Nefrologia e Dialisi, Azienda Ospedaliera San Gerardo</name>
      <address>
        <city>Monza</city>
        <zip>20900</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>(+)390392339385</phone>
      <email>federico.pieruzzi@unimib.it</email>
    </contact>
    <investigator>
      <last_name>Federico Pieruzzi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Città della Salute e della Scienza di Torino</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>(+) 390116335593</phone>
      <email>ezio.ghigo@unito.it</email>
    </contact>
    <investigator>
      <last_name>Ezio Ghigo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Integrata Di Verona</name>
      <address>
        <city>Verona</city>
        <zip>37124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>(+) 390458126564</phone>
      <email>domenico.girelli@univr.it</email>
    </contact>
    <investigator>
      <last_name>Domenico Girelli</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pauls Stradins Clinical University Hospital</name>
      <address>
        <city>Riga</city>
        <zip>LV-1002</zip>
        <country>Latvia</country>
      </address>
    </facility>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>(+) 37167069963</phone>
      <email>ainars_rudzitis@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Ainars Rudzitis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Szpital Uniwersytecki</name>
      <address>
        <city>Krakow</city>
        <zip>30-033</zip>
        <country>Poland</country>
      </address>
    </facility>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>(+) 48600294141</phone>
      <email>mmsocha@cyf-kr.edu.pl</email>
    </contact>
    <investigator>
      <last_name>Stanislawa Bazan-Socha</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instytut Kardiologii im Prymasa Tysiaclecia Kardynala Stefana Wyszynskiego</name>
      <address>
        <city>Warszawa</city>
        <zip>04-628</zip>
        <country>Poland</country>
      </address>
    </facility>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>(+) 48694558761</phone>
      <email>mklopotowski@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Mariusz Klopotowski</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Uniwersytecki Szpital Kliniczny im. Jana Mikulicza Radeckiego we Wroclawiu</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-556</zip>
        <country>Poland</country>
      </address>
    </facility>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>(+) 48717332501</phone>
      <email>magdalena.krajewska@umed.wroc.pl</email>
    </contact>
    <investigator>
      <last_name>Magdelena Krajewska</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar e Universitário de Coimbra EPE</name>
      <address>
        <city>Coimbra</city>
        <zip>3000-459</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>(+) 351239400477 x13142</phone>
      <email>hesperto@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Esperto Helder</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Senhora da Oliveira - Guimaraes, E.P.E</name>
      <address>
        <city>Guimaraes</city>
        <zip>4835-044</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>(+) 351916008636</phone>
      <email>olgazevedo@yahoo.com.br</email>
    </contact>
    <investigator>
      <last_name>Olga Azevedo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar Lisboa Norte, E.P.E. - Hospital de Santa Maria</name>
      <address>
        <city>Lisboa</city>
        <zip>1649-035</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>(+) 351 96 472 85 26</phone>
      <email>patricio.aguiar@campus.ul.pt</email>
    </contact>
    <investigator>
      <last_name>Patrício Aguiar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fundeni Clinical Institute</name>
      <address>
        <city>Bucharest</city>
        <zip>22328</zip>
        <country>Romania</country>
      </address>
    </facility>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>(+) 40722792429</phone>
      <email>gener732000@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Gener Ismail</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>General Hospital Slovenj Gradec</name>
      <address>
        <city>Slovenj Gradec</city>
        <zip>2380</zip>
        <country>Slovenia</country>
      </address>
    </facility>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>(+) 38641430509</phone>
      <email>bojan.vujkovac@sb-sg.si</email>
    </contact>
    <investigator>
      <last_name>Bojan Vujkovac</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Torrecárdenas</name>
      <address>
        <city>Almeria</city>
        <zip>4009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>(+) 34950016342</phone>
      <email>dra_garofano@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Remedios Garofano Lopez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall d'Hebrón - PPDS</name>
      <address>
        <city>Barcelona</city>
        <zip>8035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>(+) 34 934893141</phone>
      <email>mcamprodon@vhebron.net</email>
    </contact>
    <investigator>
      <last_name>Maria Camprodon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <investigator>
      <last_name>Aquilino Sanchez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Quironsalud Zaragoza</name>
      <address>
        <city>Zaragoza</city>
        <zip>50012</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>(+) 34670285339</phone>
      <email>giraldocastellano@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Pilar Giraldo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska Universitetssjukhuset</name>
      <address>
        <city>Göteborg</city>
        <zip>SE-41345</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>(+) 46768688059</phone>
      <email>dimitrios.chantzichristos@vgregion.se</email>
    </contact>
    <investigator>
      <last_name>Dimitrios Chantzichristos</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Akademiska Sjukhuset I Uppsala</name>
      <address>
        <city>Uppsala</city>
        <zip>75185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>(+) 460186119297</phone>
      <email>andreas.kindmark@medsci.uu.se</email>
    </contact>
    <investigator>
      <last_name>Andreas Kindmark</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Communal noncommercial enterprise of Lviv Regional Council Lviv Regional Clinical Hospital</name>
      <address>
        <city>Lviv</city>
        <zip>79000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>(+) 380322786258</phone>
      <email>dr.orchyk@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Orest Semeryak</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Bosnia and Herzegovina</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Croatia</country>
    <country>Finland</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Latvia</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Romania</country>
    <country>Slovenia</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Ukraine</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 7, 2020</study_first_submitted>
  <study_first_submitted_qc>April 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 12, 2021</study_first_posted>
  <last_update_submitted>August 10, 2021</last_update_submitted>
  <last_update_submitted_qc>August 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fabry Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_access_criteria>IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://vivli.org/ourmember/takeda/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

